Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma
Wesley O. Greaves(The University of Texas MD Anderson Cancer Center), Rajyalakshmi Luthra, Bedia A. Barkoh(The University of Texas MD Anderson Cancer Center), John Galbincea(The University of Texas MD Anderson Cancer Center), Michael A. Davies(AstraZeneca (United Kingdom)), Alexander J. Lazar(Cleveland Clinic), Kenneth Aldape(National Institutes of Health), Hui Yao(Wannan Medical College), L. Jeffrey Medeiros(The University of Texas MD Anderson Cancer Center), Shalini Verma(The University of Texas MD Anderson Cancer Center), Keyur P. Patel(The University of Texas MD Anderson Cancer Center)
Cited by 217
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Validation of the ITS2 Region as a Novel DNA Barcode for Identifying Medicinal Plant Species
|PLoS ONE|2010|1.7k
Use of ITS2 Region as the Universal DNA Barcode for Plants and Animals
|PLoS ONE|2010|1.2k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k